The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Characteristics and survival of patients with advanced cancer and TP53 mutations in phase I clinical trials.
Rabih Said
No relevant relationships to disclose
Yang Ye
No relevant relationships to disclose
David S. Hong
No relevant relationships to disclose
Filip Janku
Research Funding - Biocartis; Novartis; Roche; Transgenomic; Trovagene
Siqing Fu
No relevant relationships to disclose
Aung Naing
No relevant relationships to disclose
Jennifer J. Wheler
No relevant relationships to disclose
Razelle Kurzrock
No relevant relationships to disclose
Christoforos Thomas
No relevant relationships to disclose
Gary A. Palmer
No relevant relationships to disclose
Kenneth R. Hess
No relevant relationships to disclose
Robert A. Wolff
Consultant or Advisory Role - Lilly
Apostolia Maria Tsimberidou
Research Funding - Baxter ; Celgene; Cell Therapeutics